RecruitingPhase 3NCT06022939
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Studying AL amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Patrick A HagenSWOG Cancer Research Network
- Intervention
- Autologous Hematopoietic Stem Cell Transplantation(procedure)
- Enrollment
- 338 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2030
Study locations (30)
- Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States
- Smilow Cancer Hospital Care Center - Guilford, Guilford, Connecticut, United States
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States
- Carle at The Riverfront, Danville, Illinois, United States
- Carle Physician Group-Effingham, Effingham, Illinois, United States
- Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- Carle Cancer Center, Urbana, Illinois, United States
- Mission Cancer and Blood - Ankeny, Ankeny, Iowa, United States
- Iowa Methodist Medical Center, Des Moines, Iowa, United States
- Mission Cancer and Blood - Des Moines, Des Moines, Iowa, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06022939 on ClinicalTrials.govOther trials for AL amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06963216A Study Investigating Coagadex in the Treatment AFXD Associated With AL AmyloidosisKedrion S.p.A.
- RECRUITINGPHASE3NCT07388602A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)Sinocelltech Ltd.
- RECRUITINGPHASE1, PHASE2NCT07266116Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis PatientsShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- RECRUITINGNCT07448935One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMSFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGNCT07448779Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and TreatmentFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGPHASE2NCT07110844Teclistamab-Daratumumab in AL AmyloidosisSuzanne Lentzsch, MD
- RECRUITINGPHASE1NCT07250269Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL AmyloidosisGracell Biotechnologies (Shanghai) Co., Ltd.
- RECRUITINGNCT07172243BE.Amycon Biobank & Data Registry UZ LeuvenUniversitaire Ziekenhuizen KU Leuven